Published on 1 Dec 2023 on Zacks via Yahoo Finance
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
Annovis Bio ANVS is a clinical-stage drug platform company addressing neurodegenerative diseases, such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).
The company’s lead product candidate is buntanetap (formerly ANVS402 or posiphen), an investigational, oral translational inhibitor of neurotoxic aggregating proteins. This mode of action is expected to lead to a lower level of neurotoxic proteins and, consequently, less toxicity in the brain.
Currently, buntanetap is being evaluated in a late-stage study in early PD patients. The drug is also being evaluated in a phase II/III study in mild-to-moderate AD patients.